| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | 0.15 | 6e-05 |
| mRNA | PLX4720 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0001 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.14 | 0.0002 |
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.14 | 0.0003 |
| mRNA | quizartinib | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0005 |
| mRNA | Ki8751 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0008 |
| mRNA | Tamoxifen | CTRPv2 | pan-cancer | AAC | 0.12 | 0.001 |
| mRNA | masitinib | CTRPv2 | pan-cancer | AAC | 0.12 | 0.001 |
| mRNA | BRD-A05715709 | CTRPv2 | pan-cancer | AAC | 0.18 | 0.001 |
| mRNA | MGCD-265 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.001 |